CureVag AG Receives $110m in Additional Funding

CureVag AG announced that it has received $110 million in funding led by new investor Baillie Gifford & Co. on November 3, 2015. The transaction included participation from new investors Chartwave Limited, Coppel Family, Northview, Elma Investments Ltd, and Sigma Group. Existing investors dievini Hopp BioTech holding GmbH & Co KG and Bill & Melinda Gates Foundation Asset Trust also participated in this round. The company has received $330 million in funding till date.

CureVac AG, a biopharmaceutical company that develops messenger RNA (mRNA) therapeutics. It offers RNActive, which are mRNA-based cancer immunotherapies and prophylactic vaccines against infectious diseases; RNArt molecular therapies that are designed to trigger the body’s own production of therapeutic proteins; and RNAdjuvant RNA encoded antibodies. The company also researches and develops active ingredients for the treatment of cancer, as well as for protection against infectious diseases; and RNActive-based rabies vaccines. The company was founded in 2000 and is based in Tubingen, Germany.